The efficacy and safety of tocilizumab in juvenile localised scleroderma patients: a retrospective cohort study in Eastern China
Tocilizumab appears to be a safe and effective adjunctive therapy for juvenile localised scleroderma, particularly when initiated early, as it reduces relapse risk and the need for prolonged glucocorticosteroid use. It remains a promising adjunct in refractory or severe cases requiring long-term management.
Authors
- Yang Shen (ORCID: https://orcid.org/0000-0002-6055-5046)
- Denghuan Chen
- Dingyun Chen
- Shouwei Hang
- Na Li
- Xing Wang (ORCID: https://orcid.org/0000-0002-8537-7186)
- Jing Shan (ORCID: https://orcid.org/0000-0002-4343-6870)
- Daliang Xu
- Yutong Gao
- Xiaoliang He
Institutions
- The University of Sydney (AU)
Publication Details
- Journal
- Advances in Rheumatology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1186/s42358-025-00511-1
- Citations
- 1
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.47